A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BMS-986224 in Participants With Varying Degrees of Renal Function
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2019
At a glance
- Drugs BMS-986224 (Primary)
- Indications Chronic heart failure
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 28 Jan 2019 Planned End Date changed from 3 Jan 2019 to 21 Mar 2019.
- 28 Jan 2019 Planned primary completion date changed from 3 Jan 2019 to 20 Mar 2019.
- 28 Aug 2018 Status changed from not yet recruiting to recruiting.